What the Clinical Trials Actually Measured — and Why the Distinctions Matter

Yoon Hang Kim MD

Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

About Dr. Kim

Yoon Hang Kim MD is a board-certified preventive medicine physician with more than 20 years of clinical experience in integrative and functional medicine. He completed an integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certification in medical acupuncture. His clinical focus includes low-dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity. He is the author of 8 books and more than 25 peer-reviewed articles.

Professional: www.yoonhangkim.com   |   Clinical: www.directintegrativecare.com

If you've come across claims that IV EDTA chelation can clean out your arteries, reverse coronary plaque, or stand in for conventional heart disease treatment — I understand the appeal. A nonsurgical infusion that dissolves plaque sounds like exactly the kind of answer people are hoping for.

But when I look carefully at what the clinical trials actually measured, the picture is more nuanced than either the marketing or the flat dismissals suggest.

The short version: no trial has ever directly shown that IV EDTA chelation shrinks or removes coronary artery plaque. One major trial did find a modest reduction in cardiovascular events after a heart attack — a real, statistically significant result. But the follow-up trial, designed to confirm it in the patients who appeared to benefit most, did not reproduce that benefit. Throughout all of this, it's worth holding three separate questions apart, because they get constantly conflated: Does chelation remove metals from the body? Does it shrink plaque inside an artery? And does it prevent heart attacks? Those are three different outcomes, and the evidence on each is different.

What the Major Trials Actually Showed

TACT (2013)

The Trial to Assess Chelation Therapy (TACT) was the first large, rigorous test of the idea. It randomized 1,708 patients who had already had a myocardial infarction to receive either an EDTA-based infusion regimen or placebo. The primary composite outcome — death, reinfarction, stroke, coronary revascularization, or hospitalization for angina — occurred in 26% of the chelation group versus 30% of the placebo group, a hazard ratio of 0.82 (95% CI 0.69–0.99).1

That result was statistically significant, and I don't want to wave it away — it surprised a lot of skeptics, myself included. But two caveats matter. First, the benefit rested on the composite. The individual hard endpoints — death, MI, stroke — did not reach statistical significance on their own; the softer components carried much of the weight. Second, the trial's own investigators were explicit that these results did not justify the routine use of chelation.1

There's one more attribution problem. The TACT infusion wasn't EDTA by itself. It was a multicomponent solution — disodium EDTA plus vitamin C, B vitamins, electrolytes, procaine, and heparin. So even the modest signal that was observed can't be pinned cleanly on EDTA.1

TACT2 (2024)

Here's the detail that makes the next chapter compelling. In the original TACT, the single most striking signal came from patients with diabetes, who showed roughly a 41% relative reduction in combined events in a prespecified subgroup. That subgroup was the strongest reason to take the whole thing seriously — so TACT2 was built specifically to test it.1,6

TACT2 enrolled patients with both diabetes and a prior heart attack — the exact population where you'd most expect chelation to prove itself. The treatment did what it was supposed to do mechanistically: median blood lead levels fell by about 61%. But the clinical outcomes landed almost on top of each other. A primary endpoint event occurred in 35.6% of the chelation group versus 35.7% of placebo, an adjusted hazard ratio of 0.93 (95% CI 0.76–1.16; P=.53).2

In plain terms: it did not reproduce the earlier benefit. Removing lead did not translate into fewer cardiovascular events in this group.2,6

And here is the point I most want to be precise about. TACT2 measured cardiovascular events, not plaque volume. No one's arteries were imaged before and after to see whether plaque shrank. So TACT2 is not a direct test of plaque removal either — it's a test of whether chelation prevents events, and in this population it did not demonstrate a statistically significant benefit.2

Why Calcium Binding Doesn't Establish Plaque Removal

The most common mechanistic claim you'll hear is that EDTA "pulls calcium out" of coronary plaque. It has surface logic: EDTA does bind calcium and other minerals so the body can excrete them.

But binding calcium circulating in the bloodstream is a very different thing from selectively extracting calcium out of an established plaque deposit and reopening a narrowed artery. That specific effect has never been demonstrated in a well-designed clinical study. The more modern and more plausible hypothesis is the one TACT2 was built to test — that removing lead or cadmium might reduce metal-associated vascular injury. The treatment removed the lead. The events didn't move. That doesn't slam the door on every possible benefit in every subgroup, but it undercuts the rationale for using chelation as a routine coronary treatment.2

Why a Lower Calcium Score Wouldn't Settle the Debate

Some advocates point to before-and-after coronary calcium scores as proof the treatment "worked." That reasoning rests on a misunderstanding of what a calcium score actually measures.

A calcium score is not a stand-in for total plaque burden or plaque stability. Serial scans carry real measurement variability. And here's the counterintuitive part that trips up even clinicians: statin therapy is associated with a shift in plaque composition toward denser, higher-attenuation calcium while reducing the low-attenuation, fibro-fatty plaque that tends to be most dangerous — and that shift toward denser calcium tracks with slower overall plaque progression. In other words, a calcium number can move in ways that reflect stabilization rather than worsening disease.3

That is exactly why a change in calcium score on its own — without corroboration from hard clinical endpoints — cannot establish that a treatment is reversing atherosclerosis or preventing events. It's also why I'd caution against reading a rising calcium score as automatically reassuring in an individual patient: composition and context matter.3

What This Means for Clinical Decision-Making

None of this means chelation has no legitimate role. For selected, clinically significant heavy-metal poisonings, chelation is an established and important treatment — but the agent is matched to the specific metal and the clinical circumstances, and the disodium EDTA regimen studied in TACT is not interchangeable with the agents used for, say, lead, mercury, or arsenic. Evidence that chelation removes a toxic metal should never be repackaged as evidence that it removes coronary plaque.2,5

Here's what the evidence supports as of this writing:

Plaque removal itself remains unproven. No trial has directly shown that IV EDTA chelation shrinks or clears coronary plaque.2

TACT found a modest, statistically significant reduction in cardiovascular events after MI — but its own authors did not endorse routine use.1

TACT2 did not reproduce that benefit in patients with diabetes and a prior MI — the group most likely to show it.2

Chelation should not replace or delay proven coronary treatments or indicated revascularization.4

The treatment carries real risk. Fatal hypocalcemia has been reported with disodium EDTA — several cases tied to formulation or administration errors — and EDTA is not FDA-approved for treating coronary heart disease. (Note the distinction between disodium EDTA and calcium disodium EDTA; they are not the same drug and are not interchangeable.)4,5

The Bottom Line

I understand why people with coronary disease look for another path. Conventional care isn't always satisfying, procedures are daunting, and a simple infusion that "cleans your arteries" is a deeply appealing story. My job as a clinician is to be honest about what the evidence shows — not what any of us wish it showed.

So, to the direct question — can chelation shrink or clear coronary plaque? There is no reliable clinical evidence that it does, and no trial has directly tested it by imaging plaque. The best event-based evidence is genuinely mixed: a modest benefit in the first trial that the confirmatory trial could not reproduce in the very group most likely to show it. That is not a basis for marketing or prescribing chelation as a plaque-removal treatment.

If you've been told otherwise, I'd encourage you to read the trials themselves. And if you're weighing a specific treatment, supplement, or claim, I'm glad to walk through the actual evidence with you.

Work with Dr. Kim

Dr. Kim offers membership-based, insurance-free telemedicine care for complex and chronic conditions — integrative and functional medicine built on a foundation of good conventional care, working alongside your existing physicians rather than replacing them. The practice is intentionally limited in size to preserve focused, high-touch care, with membership currently available in Texas, Illinois, Missouri, Georgia, and Florida. Clients outside those states, including international readers, can arrange an educational consultation session.

To learn more or request a discovery call, visit www.directintegrativecare.com. For in-depth clinical articles and evidence reviews, visit ifmsynergy.com.

Dr. Kim is the author of MCAS: Epidemic in Plain Sight and LDN Primer, both available on Amazon, and the founder of the LDN Support Group.

References

1. Lamas GA, Goertz C, Boineau R, et al. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA. 2013;309(12):1241–1250. doi:10.1001/jama.2013.2107

2. Lamas GA, Anstrom KJ, Navas-Acien A, et al. Edetate disodium–based chelation for patients with a previous myocardial infarction and diabetes: TACT2 randomized clinical trial. JAMA. 2024;332(10):794–803. doi:10.1001/jama.2024.11463

3. van Rosendael AR, van den Hoogen IJ, Gianni U, et al. Association of statin treatment with progression of coronary atherosclerotic plaque composition. JAMA Cardiol. 2021;6(11):1257–1266. doi:10.1001/jamacardio.2021.3055

4. Sultan S, Murarka S, et al. Chelation therapy in cardiovascular disease: an update. Expert Rev Clin Pharmacol. 2017;10(8):843–854. doi:10.1080/17512433.2017.1339601

5. Centers for Disease Control and Prevention. Deaths associated with hypocalcemia from chelation therapy — Texas, Pennsylvania, and Oregon, 2003–2005. MMWR Morb Mortal Wkly Rep. 2006;55(8):204–207. cdc.gov/mmwr/preview/mmwrhtml/mm5508a3.htm

6. National Center for Complementary and Integrative Health. In a large multicenter trial, chelation therapy did not reduce cardiovascular disease events in patients with diabetes and a history of heart attack. August 2024. nccih.nih.gov/research/research-results